Trial Profile
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 25 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to change in strategy.
- 25 Oct 2016 New trial record